239 related articles for article (PubMed ID: 4069288)
1. Comparison of the effectivity of two diaminocyclohexane Pt-complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance induction and cross-resistance studies with Pt-complexes.
Hrubisko M; Balázová E; Ujházy V
Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
5. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of four polymer bound trans-1,2-diaminocyclohexaneplatinum(II)-4-carboxyphtalate complexes tested in different model systems.
Balázová E; Hrubisko M; Drobník J; Ujházy V
Neoplasma; 1986; 33(6):665-70. PubMed ID: 3808121
[TBL] [Abstract][Full Text] [Related]
7. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro effectivity of some platinum complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1984; 31(6):641-7. PubMed ID: 6395026
[TBL] [Abstract][Full Text] [Related]
10. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.
Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW
J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793
[TBL] [Abstract][Full Text] [Related]
12. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
13. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
14. Growth, flow cytometric, and karyological characterization of L1210 cell sublines resistant to various Pt derivatives.
Hrubisko M; Kysela B; Kuliffay P
Neoplasma; 1989; 36(4):401-10. PubMed ID: 2770927
[TBL] [Abstract][Full Text] [Related]
15. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
17. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
[TBL] [Abstract][Full Text] [Related]
19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and antitumor activity of new platinum(IV) trans-carboxylate complexes: crystal structure of [Pt(cis-1,4-DACH)trans-(acetate)2Cl2].
Shamsuddin S; Santillan CC; Stark JL; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 1998 Aug; 71(1-2):29-35. PubMed ID: 9755489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
